Non Obstructive Hypertrophic Cardiomyopathy clinical trials

Explore recruiting non obstructive hypertrophic cardiomyopathy clinical trials.

Recruiting non obstructive hypertrophic cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Obstructive Hypertrophic Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM

Austria, Germany, Belgium, France, Portugal, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Czechia, Belgium, Norway, Spain, Poland, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Poland, Spain, Italy, Hungary, France, Germany +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)

Italy, Romania, France, Belgium, Sweden, Portugal +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Obstructive Hypertrophic Cardiomyopathy trials by city

Non Obstructive Hypertrophic Cardiomyopathy in Toronto Non Obstructive Hypertrophic Cardiomyopathy in Vancouver Non Obstructive Hypertrophic Cardiomyopathy in Montreal Non Obstructive Hypertrophic Cardiomyopathy in Calgary Non Obstructive Hypertrophic Cardiomyopathy in Edmonton Non Obstructive Hypertrophic Cardiomyopathy in Ottawa Non Obstructive Hypertrophic Cardiomyopathy in Winnipeg Non Obstructive Hypertrophic Cardiomyopathy in Quebec City Non Obstructive Hypertrophic Cardiomyopathy in Hamilton Non Obstructive Hypertrophic Cardiomyopathy in Kitchener Non Obstructive Hypertrophic Cardiomyopathy in London Non Obstructive Hypertrophic Cardiomyopathy in Halifax Non Obstructive Hypertrophic Cardiomyopathy in New York Non Obstructive Hypertrophic Cardiomyopathy in Los Angeles Non Obstructive Hypertrophic Cardiomyopathy in Chicago Non Obstructive Hypertrophic Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease